What is claimed is:
1. A pharmaceutical composition comprising a dispersion, said dispersion comprising an agent selected from the group consisting of inhibitors of angiotensin converting enzymes and inhibitors of neutral endopeptidase, dispersed in a lipoidic vehicle.
2. The composition of claim 1 wherein said agent is sampatrilat.
3. The composition of claim 1 wherein said lipoidic vehicle is a glyceride.
4. The composition of claim 3 wherein said glyceride is selected from the group consisting of medium chain glycerides and caprylocaproyl macrogolglycerides, and mixtures thereof.
5. The composition of claim 4 wherein said glyceride is a medium chain glyceride.
6. The composition of claim 5 wherein said medium chain glyceride is selected from the group consisting of medium chain monoglycerides, medium chain diglycerides, capryliccapric triglyceride, glyceryl monolaurate, capryliccapric glycerides, glycerylmonocaprylate, glyceryl monodicaprylate, capryliccapric linoleic triglyceride, and capryliccapricsuccinic triglyceride.
7. The composition of claim 4 wherein said glyceride is a caprylocaproyl macrogolglyceride.
8. The composition of claim 7 wherein said caprylocaproyl macrogolglyceride is a polyethylene glycosylated glyceride.
9. The composition of claim 8 wherein said polyethylene glycosylated glyceride is selected from the group consisting of mixtures of monoglycerides, diglycerides, and triglycerides and monoesters and diesters of polyethylene glycol, polyethylene glycosylated almond glycerides, polythylene glycosylated corn glycerides, and polyethylene glycosylated capryliccapric triglyceride.
10. The composition of claim 1, and further comprising a sorbent.
11. The composition of claim 10 wherein said sorbent is dicalcium phosphate.
12. A method for the treatment or prevention of cardiovascular disorders including hypertension and heart failure comprising the step of administering a pharmaceutically effective amount of a formulation as defined in claim 1 to a subject in need of such treatment or prevention.
13. The use of a pharmaceutically effective amount of a formulation as defined in claim 1 for treating or preventing cardiovascular disorders including hypertension and heart failure.
14. A method for the manufacture of a formulation comprising the steps of dispersing an agent selected from the group consisting of inhibitors of angiotensin converting enzymes and inhibitors of neutral endopeptidase, in a lipoidic vehicle.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A sealed linear actuator unit, comprising:
an outer rail, having a substantially cylindrical shape which includes a hollow portion therein, and further includes a slit-opening portion disposed along an axial direction thereof;
an inner block, disposed in the hollow portion of the outer rail, and which is movable along a longitudinal direction of the outer rail;
a driving means, which is coupled to the inner block in the hollow portion of the outer rail, and causes the inner block to reciprocate along the longitudinal direction of the outer rail;
a slide plate, disposed outside of the slit-opening portion of the outer rail, and which is coupled to the inner block through the slit-opening portion;
a cover belt, which is tensioned between both ends in the longitudinal direction of the outer rail so as to cover the slit-opening portion;
a belt-guiding member, including a separating portion which separates the cover belt from the outer rail corresponding to movement of the slide plate so as to cause the cover belt to climb over the slide plate; and
a seal member fixed to the belt-guiding member, which seals between the belt-guiding member and the cover belt and between the belt-guiding member and the outer rail so as to prevent dust from getting into the hollow portion of the outer rail, wherein the seal member further includes,
a pair of end seal portions, which press the cover belt against the outer rail on a front side and a rear side in a moving direction of the slide plate, and
a pair of side seal portions, which couple the pair of end seal portions with one another, and are held in contact with the outer rail along the moving direction of the slide plate.
2. The sealed linear actuator unit according to claim 1, wherein the end seal portions and side seal portions are continuous with each other without spacing therebetween.
3. The sealed linear actuator unit according to claim 2, wherein the side plate has a guiding groove for causing the cover belt to pass therethrough, and the belt-guiding member includes a cover plate being fixed to the slide plate so as to cover the guiding groove.
4. The sealed linear actuator unit according to claim 3, wherein the seal member includes,
a pair of flange portions disposed at the end seal portions, and
a pair of side frames disposed at the side seal portions coupling the pair of flange portions with one another, in such a manner that the seal member is formed into a rectangular frame shape, and
wherein the side frames of the seal member are arranged so as to be held in contact with a side of a lower surface of the slide pate, and the seal member is integrated with the slide plate so as to be fixed to the cover plate of the belt-guiding member.